NCT05338775

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination With Checkpoint Inhibition for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 74 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the safety and tolerability of talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.

Conditions

• Relapsed/ Refractory Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Talquetamab	Talquetamab will be administered as a subcutaneous (SC) injection.
DRUG	Teclistamab	Teclistamab will be administered as a SC injection.
DRUG	PD-1 Inhibitor	The PD-1 inhibitor will be administered as an intravenous injection.

Timeline

• Start date: 2022-05-25
• Primary completion: 2025-05-22
• Completion: 2027-05-03
• First posted: 2022-04-21
• Last updated: 2026-04-13

Locations

19 sites across 4 countries: United States, France, Germany, Spain

Regulatory

• FDA-regulated drug study